Potential targets for anti-liver fibrosis

Yaoxue Xuebao

Volumn 49, Issue 10, 2014, Pages 1365-1371

  Zhao, Shuang Shuang ^a   Shao, Rong Guang ^a   He, Hong Wei ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Extracellular matrix; Hepatic stellate cell; Liver fibrosis; Transforming growth factor 1

Indexed keywords

CD51 ANTIGEN; COLLAGEN; LIVER PROTECTIVE AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; DISEASE CONTROL; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; PROPHYLAXIS; LIVER; METABOLISM; PATHOLOGY;

COLLAGEN; HUMANS; INTEGRIN ALPHAV; LIVER; LIVER CIRRHOSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84919919006     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Bataller R, Brenner DA. Liver fibrosis [J]. J Clin Invest, 2005, 115: 209-218.
2. Fallowfield J, Hayes P. Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible? [J]. Clin Med, 2011, 11: 179-183.
3. Guo J, Friedman SL. Hepatic fibrogenesis [J]. Semin Liver Dis, 2007, 27: 413-426.
4. Wu JY, Liu GT. The roles of Kupffer cells in the development and regression of liver fibrosis [J]. Acta Pharm Sin, 2008, 43: 884-889.
5. Liu B, Zhang X, Zhang FC, et al. Aberrant TGF-betal signaling contributes to the development of primary biliary cirrhosis in murine model [J]. World J Gastroenterol, 2013, 19: 5828-5836.
6. Lee WR, Kim KH, An HJ, et al. Apamin inhibits hepatic fibrosis through suppression of transforming growth factor β-induced hepatocyte epithelial-mesenchymal transition [J]. Biochem Biophys Res Commun, 2014, 450: 195-201.
7. 4-induced hepatic fibrosis in mice by vaccinating against TGF-betal [J]. PLoS One, 2013, 8: e82190.
8. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models [J]. Eur Respir Rev, 2011, 20: 85-97.
9. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors [J]. J Clin Invest, 1998, 102: 538-549.
10. Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse [J]. Hepatology, 2002, 36: 850-860.
11. Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice [J]. FASEB J, 2006, 20: 444-454.
12. Cong M, Liu T, Wang P, et al. Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis [J]. Am J Pathol, 2013, 182: 1607-1616.
13. Chan CC, Hwang SJ, Lee FY, et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis [J]. Scand J Gastroenterol, 1997, 32: 942-946.
14. Chen J, Zeng B, Yao H, et al. The effect of TLR4/7 on the TGF-β-induced Smad signal transduction pathway in human keloid [J]. Burns, 2013, 39: 465-472.
15. Seki E, De Minicis S, Österreicher CH, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis [J]. Nat Med, 2007, 13: 1324-1332.
16. Bai T, Lian LH, Wu YL, et al. Thymoquinone attenuates liver fibrosis via PI3K. and TLR4 signaling pathways in activated hepatic stellate cells [J]. Int Immunopharmacol, 2013, 15: 275-281.
17. Qian H, Shi J, Fan TT, et al. Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats [J]. World J Gastroenterol, 2014, 20: 1822-1832.
18. Shi M, Zhu J, Wang R, et al. Latent TGF-beta structure and activation [J]. Nature, 2011, 474: 343-349.
19. Wipff PJ, Rifkin DB, Meister JJ, et al. Myofibroblast contraction activates latent TGF-beta 1 from the extracellular matrix [J]. J Cell Biol, 2007, 179: 1311-1323.
20. Henderson NC, Arnold TD, Katamura Y, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs [J]. Nat Med, 2013, 19: 1617-1624.
21. Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis [J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294: G357-G362.
22. Hézode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C [J]. Hepatology, 2005, 42: 63-71.
23. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis [J]. Nat Med, 2006, 12: 671-676.
24. Chen S, Wu B, Xu S, et al. Suppression of CB1 cannabinoid receptor by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats [J]. PLoS One, 2012, 7: e50850.
25. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver [J]. Gastroenterology, 2005, 128: 742-755.
26. Munoz-Luque J, Ros J, Fernandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats [J]. J Pharmacol Exp Ther, 2007, 324: 475-483.
27. Caraceni P, Domenicali M, Giannone F, et al. The role of the endocannabinoid system in liver diseases [J]. Best Pract Res Clin Endocrinol Metab, 2009, 23: 65-77.
28. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis [J]. J Exp Med, 2010, 207: 1589-1597.
29. Simonsson M, Heldin CH, Ericsson J, et al. The balance between acetylation and deacetylation controls Smad7 stability [J]. J Biol Chem, 2005, 280: 21797-21803.
30. Bian E, Huang C, Wang H, et al. Repression of Smad7 mediated by DNMT1 determines hepatic stellate cell activation and liver fibrosis in rats [J]. Toxicol Lett, 2014, 224: 175-185.
31. Dooley S, Hamzavi J, Ciuclan L, et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage [J]. Gastroenterology, 2008, 135: 642-659.
32. 4-dependent liver damage and fibrogenesis in mice [J]. J Cell Mol Med, 2008, 12: 2130-2144.
33. Zhu L, Wang L, Wang X, et al. Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury [J]. PLoS One, 2011, 6: e17415.
34. Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats [J]. Gastroenterology, 2003, 125: 178-191.
35. Haider SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis [J]. Exp Cell Res, 2005, 307: 231-246.
36. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis [J]. J Clin Invest, 2003, 112: 1383-1394.
37. Wolf G. Novel aspects of the renin-angiotensin-aldosterone-system [J]. Front Biosci, 2008, 13: 4993-5005.
38. Uhal BD, Li X, Piasecki CC, et al. Angiotensin signaling in pulmonary fibrosis [J]. Int J Biochem Cell Biol, 2012, 44: 465-468.
39. Yang L, Bataller R, Dulyx J, et al. Attenuated hepatic inflammation and fibrosis in angiotensin type la receptor deficient mice [J]. J Hepatol, 2005, 43: 317-323.
40. Colmenero J, Bataller R, Sancho-Bru P, et al. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C [J]. Am J Physiol Gastrointest Liver Physiol, 2009, 297: G726-G734.
41. Granzow M, Schierwagen R, Klein S, et al. Angiotensin-II type 1 receptor-mediated Janus-kinase-2 activation induces liver fibrosis [J]. Hepatology, 2014, 60: 334-348.
42. Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones [J]. J Biol Chem, 2010, 285: 9780-9791.
43. Wang Z, Xu JP, Zheng YC, et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats [J]. Hepatobiliary Pancreat Dis Int, 2011, 10: 64-71.
44. Bae MA, Rhee SD, Jung WH, et al. Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARy agonist KR62776 [J]. Arch Pharm Res, 2010, 33: 433-442.
45. Yang MD, Chiang Y, Higashiyama R, et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor y in hepatic stellate cells for their antifibrotic effect [J]. Hepatology, 2012, 55: 1271-1281.
46. Attia YM, Elalkamy EF, Hammam OA, et al. Telmisartan, an ATI receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection [J]. Parasit Vectors, 2013, 6: 199.
47. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J]. N Engl J Med, 2006, 355: 2297-2307.
48. Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis [J]. Hepatology, 2011, 53: 209-218.
49. Ogawa T, Iizuka M, Sekiya Y, et al. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells [J]. Biochem Biophys Res Commun, 2010, 391: 316-321.
50. Kwiecinski M, Noetel A, Elfimova N, et al. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction [J]. PLoS One, 2011, 6: e24568.
51. Kwiecinski M, Elfimova N, Noetel A, et al. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29 [J]. Lab Invest, 2012, 92: 978-987.
52. Zhang Y, Wu L, Wang Y, et al. Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury [J]. J Biol Chem, 2012, 287: 14851-14862.
53. Weng HL, Wang BE, Jia JD, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study [J]. Clin Gastroenterol Hepatol, 2005, 3: 819-828.
54. Bahcecioglu IH, Koca SS, Poyrazoglu OK, et al. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis [J]. Inflammation, 2008, 31: 215-221.
55. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis [J]. J Hepatol, 2003, 38: 419-425.
56. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis [J]. Gastroenterology, 2004, 127: 1497-1512.
57. Hattori S, Dhar DK, Hara N, et al. FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect on liver cirrhosis through downregulation of Runx2 [J]. Lab Invest, 2007, 87: 591-601.
58. He H, Mennone A, Boyer JL, et al. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-Iigated rats and human hepatic cells [J]. Hepatology, 2011, 53: 548-557.
59. Yu DK, Gao Y, Zhang CX, et al. Whole genome analysis of the effect of retinoic acid on liver fibrosis [J]. Chin Pharmacol Bull, 2013, 29: 1213-1216.